This culminated in the development of a single heterobivalent conjugated radiotracer targeting both GRPR and PSMA to effectively target multiple bio-markers, thereby enhancing its applicability in the detection, staging, and treatment of both primary and metastatic PCa. The gene discussed is FOLH1; the disease is posterior cortical atrophy.